Skip to main content
Erschienen in: Acta Neuropathologica 4/2009

01.10.2009 | Original Paper

Neuronal loss in Pelizaeus–Merzbacher disease differs in various mutations of the proteolipid protein 1

verfasst von: Anders A. F. Sima, Christopher R. Pierson, Randall L. Woltjer, Grace M. Hobson, Jeffrey A. Golden, William J. Kupsky, Galen M. Schauer, Thomas D. Bird, Robert P. Skoff, James Y. Garbern

Erschienen in: Acta Neuropathologica | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Mutations affecting proteolipid protein 1 (PLP1), the major protein in central nervous system myelin, cause the X-linked leukodystrophy Pelizaeus–Merzbacher disease (PMD). We describe the neuropathologic findings in a series of eight male PMD subjects with confirmed PLP1 mutations, including duplications, complete gene deletion, missense and exon-skipping. While PLP1 mutations have effects on oligodendrocytes that result in mutation-specific degrees of dysmyelination, our findings indicate that there are also unexpected effects in the central nervous system resulting in neuronal loss. Although length-dependent axonal degeneration has been described in PLP1 null mutations, there have been no reports on neuronal degeneration in PMD patients. We now demonstrate widespread neuronal loss in PMD. The patterns of neuronal loss appear to be dependent on the mutation type, suggesting selective vulnerability of neuronal populations that depends on the nature of the PLP1 disturbance. Nigral neurons, which were not affected in patients with either null or severe misfolding mutations, and thalamic neurons appear particularly vulnerable in PLP1 duplication and deletion patients, while hippocampal neuronal loss was prominent in a patient with complete PLP1 gene deletion. All subjects showed cerebellar neuronal loss. The patterns of neuronal involvement may explain some clinical findings, such as ataxia, being more prominent in PMD than in other leukodystrophies. While the precise pathogenetic mechanisms are not known, these observations suggest that defective glial functions contribute to neuronal pathology.
Literatur
1.
Zurück zum Zitat Anderson TJ, Schneider A, Barrie JA et al (1998) Late-onset neurodegeneration in mice with increased dosage of the proteolipid protein gene. J Comp Neurol 394:506–519PubMedCrossRef Anderson TJ, Schneider A, Barrie JA et al (1998) Late-onset neurodegeneration in mice with increased dosage of the proteolipid protein gene. J Comp Neurol 394:506–519PubMedCrossRef
2.
Zurück zum Zitat Baumann N, Pham-Dinh D (2001) Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 81:871–927PubMed Baumann N, Pham-Dinh D (2001) Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 81:871–927PubMed
3.
Zurück zum Zitat Boison D, Stoffel W (1994) Disruption of the compacted myelin sheath of axons of the central nervous system in proteolipid protein-deficient mice. Proc Natl Acad Sci USA 91:11709–11713PubMedCrossRef Boison D, Stoffel W (1994) Disruption of the compacted myelin sheath of axons of the central nervous system in proteolipid protein-deficient mice. Proc Natl Acad Sci USA 91:11709–11713PubMedCrossRef
4.
Zurück zum Zitat Bond C, Si X, Crisp M et al (1997) Family with Pelizaeus–Merzbacher disease/X-linked spastic paraplegia and a nonsense mutation in exon 6 of the proteolipid protein gene. Am J Med Genet 71:357–360PubMedCrossRef Bond C, Si X, Crisp M et al (1997) Family with Pelizaeus–Merzbacher disease/X-linked spastic paraplegia and a nonsense mutation in exon 6 of the proteolipid protein gene. Am J Med Genet 71:357–360PubMedCrossRef
5.
Zurück zum Zitat Boucher SE, Cypher MA, Carlock LR, Skoff RP (2002) Proteolipid protein gene modulates viability and phenotype of neurons. J Neurosci 22:1772–1783PubMed Boucher SE, Cypher MA, Carlock LR, Skoff RP (2002) Proteolipid protein gene modulates viability and phenotype of neurons. J Neurosci 22:1772–1783PubMed
6.
Zurück zum Zitat Carango P, Funanage VL, Quiros RE, Debruyn CS, Marks HG (1995) Overexpression of DM20 messenger RNA in two brothers with Pelizaeus–Merzbacher disease. Ann Neurol 38:610–617PubMedCrossRef Carango P, Funanage VL, Quiros RE, Debruyn CS, Marks HG (1995) Overexpression of DM20 messenger RNA in two brothers with Pelizaeus–Merzbacher disease. Ann Neurol 38:610–617PubMedCrossRef
7.
Zurück zum Zitat Edgar JM, McLaughlin M, Yool D et al (2004) Oligodendroglial modulation of fast axonal transport in a mouse model of hereditary spastic paraplegia. J Cell Biol 166:121–131PubMedCrossRef Edgar JM, McLaughlin M, Yool D et al (2004) Oligodendroglial modulation of fast axonal transport in a mouse model of hereditary spastic paraplegia. J Cell Biol 166:121–131PubMedCrossRef
8.
Zurück zum Zitat Garbern JY, Cambi F, Tang XM et al (1997) Proteolipid protein is necessary in peripheral as well as central myelin. Neuron 19:205–218PubMedCrossRef Garbern JY, Cambi F, Tang XM et al (1997) Proteolipid protein is necessary in peripheral as well as central myelin. Neuron 19:205–218PubMedCrossRef
9.
Zurück zum Zitat Garbern JY, Yool DA, Moore GJ et al (2002) Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 125:551–561PubMedCrossRef Garbern JY, Yool DA, Moore GJ et al (2002) Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 125:551–561PubMedCrossRef
10.
Zurück zum Zitat Gow A, Friedrich VL Jr, Lazzarini RA (1994) Many naturally occurring mutations of myelin proteolipid protein impair its intracellular transport. J Neurosci Res 37:574–583PubMedCrossRef Gow A, Friedrich VL Jr, Lazzarini RA (1994) Many naturally occurring mutations of myelin proteolipid protein impair its intracellular transport. J Neurosci Res 37:574–583PubMedCrossRef
11.
Zurück zum Zitat Gow A, Lazzarini RA (1996) A cellular mechanism governing the severity of Pelizaeus–Merzbacher disease. Nat Genet 13:422–428PubMedCrossRef Gow A, Lazzarini RA (1996) A cellular mechanism governing the severity of Pelizaeus–Merzbacher disease. Nat Genet 13:422–428PubMedCrossRef
12.
Zurück zum Zitat Griffiths I, Klugmann M, Anderson T et al (1998) Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280:1610–1613PubMedCrossRef Griffiths I, Klugmann M, Anderson T et al (1998) Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280:1610–1613PubMedCrossRef
13.
Zurück zum Zitat Harding B, Ellis D, Malcolm S (1995) A case of Pelizaeus–Merzbacher disease showing increased dosage of the proteolipid protein gene. Neuropathol Appl Neurobiol 21:111–115PubMedCrossRef Harding B, Ellis D, Malcolm S (1995) A case of Pelizaeus–Merzbacher disease showing increased dosage of the proteolipid protein gene. Neuropathol Appl Neurobiol 21:111–115PubMedCrossRef
14.
Zurück zum Zitat Hodes ME, Pratt VM, Dlouhy SR (1993) Genetics of Pelizaeus–Merzbacher disease. Dev Neurosci 15:383–394PubMedCrossRef Hodes ME, Pratt VM, Dlouhy SR (1993) Genetics of Pelizaeus–Merzbacher disease. Dev Neurosci 15:383–394PubMedCrossRef
15.
Zurück zum Zitat Hudson LD, Puckett C, Berndt J, Chan J, Gencic S (1989) Mutation of the proteolipid protein gene PLP in a human X chromosome-linked myelin disorder. Proc Natl Acad Sci USA 86:8128–8131PubMedCrossRef Hudson LD, Puckett C, Berndt J, Chan J, Gencic S (1989) Mutation of the proteolipid protein gene PLP in a human X chromosome-linked myelin disorder. Proc Natl Acad Sci USA 86:8128–8131PubMedCrossRef
16.
Zurück zum Zitat Inoue K, Osaka H, Sugiyama N et al (1996) A duplicated PLP gene causing Pelizaeus–Merzbacher disease detected by comparative multiplex PCR. Am J Hum Genet 59:32–39PubMed Inoue K, Osaka H, Sugiyama N et al (1996) A duplicated PLP gene causing Pelizaeus–Merzbacher disease detected by comparative multiplex PCR. Am J Hum Genet 59:32–39PubMed
17.
Zurück zum Zitat Inoue K, Osaka H, Thurston VC et al (2002) Genomic rearrangements resulting in plp1 deletion occur by nonhomologous end joining and cause different dysmyelinating phenotypes in males and females. Am J Hum Genet 71:838–853PubMedCrossRef Inoue K, Osaka H, Thurston VC et al (2002) Genomic rearrangements resulting in plp1 deletion occur by nonhomologous end joining and cause different dysmyelinating phenotypes in males and females. Am J Hum Genet 71:838–853PubMedCrossRef
18.
Zurück zum Zitat Ip CW, Kroner A, Bendszus M et al (2006) Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. J Neurosci 26:8206–8216PubMedCrossRef Ip CW, Kroner A, Bendszus M et al (2006) Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. J Neurosci 26:8206–8216PubMedCrossRef
19.
Zurück zum Zitat Iwaki A, Muramoto T, Iwaki I et al (1993) A missense mutation in the proteolipid protein gene responsible for Pelizaeus–Merzbacher disease in a Japanese family. Hum Mol Genet 2:19–22PubMedCrossRef Iwaki A, Muramoto T, Iwaki I et al (1993) A missense mutation in the proteolipid protein gene responsible for Pelizaeus–Merzbacher disease in a Japanese family. Hum Mol Genet 2:19–22PubMedCrossRef
20.
Zurück zum Zitat Kagawa T, Ikenaka K, Inoue Y et al (1994) Glial cell degeneration and hypomyelination caused by overexpression of myelin proteolipid protein gene. Neuron 13:427–442PubMedCrossRef Kagawa T, Ikenaka K, Inoue Y et al (1994) Glial cell degeneration and hypomyelination caused by overexpression of myelin proteolipid protein gene. Neuron 13:427–442PubMedCrossRef
21.
Zurück zum Zitat Karim SA, Barrie JA, McCulloch MC et al (2007) PLP overexpression perturbs myelin protein composition and myelination in a mouse model of Pelizaeus–Merzbacher disease. Glia 55:341–351PubMedCrossRef Karim SA, Barrie JA, McCulloch MC et al (2007) PLP overexpression perturbs myelin protein composition and myelination in a mouse model of Pelizaeus–Merzbacher disease. Glia 55:341–351PubMedCrossRef
22.
Zurück zum Zitat Klugmann M, Schwab MH, Pühlhofer A et al (1997) Assembly of CNS myelin in the absence of proteolipid protein. Neuron 18:59–70PubMedCrossRef Klugmann M, Schwab MH, Pühlhofer A et al (1997) Assembly of CNS myelin in the absence of proteolipid protein. Neuron 18:59–70PubMedCrossRef
23.
Zurück zum Zitat Koeppen AH, Robitaille Y (2002) Pelizaeus–Merzbacher disease. J Neuropathol Exp Neurol 61:747–759PubMed Koeppen AH, Robitaille Y (2002) Pelizaeus–Merzbacher disease. J Neuropathol Exp Neurol 61:747–759PubMed
24.
Zurück zum Zitat Koeppen AH, Ronca NA, Greenfield EA, Hans MB (1987) Defective biosynthesis of proteolipid protein in Pelizaeus–Merzbacher disease. Ann Neurol 21:159–170PubMedCrossRef Koeppen AH, Ronca NA, Greenfield EA, Hans MB (1987) Defective biosynthesis of proteolipid protein in Pelizaeus–Merzbacher disease. Ann Neurol 21:159–170PubMedCrossRef
25.
Zurück zum Zitat Mimault C, Giraud G, Courtois V et al (1999) Proteolipoprotein gene analysis in 82 patients with sporadic Pelizaeus–Merzbacher disease: duplications, the major cause of the disease, originate more frequently in male germ cells, but point mutations do not. The Clinical European Network on Brain Dysmyelinating Disease. Am J Hum Genet 65:360–369PubMedCrossRef Mimault C, Giraud G, Courtois V et al (1999) Proteolipoprotein gene analysis in 82 patients with sporadic Pelizaeus–Merzbacher disease: duplications, the major cause of the disease, originate more frequently in male germ cells, but point mutations do not. The Clinical European Network on Brain Dysmyelinating Disease. Am J Hum Genet 65:360–369PubMedCrossRef
26.
Zurück zum Zitat Nave KA, Lai C, Bloom FE, Milner RJ (1987) Splice site selection in the proteolipid protein (PLP) gene transcript and primary structure of the DM-20 protein of central nervous system myelin. Proc Natl Acad Sci USA 84:5665–5669PubMedCrossRef Nave KA, Lai C, Bloom FE, Milner RJ (1987) Splice site selection in the proteolipid protein (PLP) gene transcript and primary structure of the DM-20 protein of central nervous system myelin. Proc Natl Acad Sci USA 84:5665–5669PubMedCrossRef
27.
Zurück zum Zitat Pelizaeus F (1885) Über eine eigenthümliche Form Spastischer Lähmung mit Cerebralerscheinungen auf hereditärer Grundlage (Multiple Sklerose). Arch Psychiatr Nervenkrankh 16:698–710CrossRef Pelizaeus F (1885) Über eine eigenthümliche Form Spastischer Lähmung mit Cerebralerscheinungen auf hereditärer Grundlage (Multiple Sklerose). Arch Psychiatr Nervenkrankh 16:698–710CrossRef
28.
Zurück zum Zitat Pham-Dinh D, Birling MC, Roussel G, Dautigny A, Nussbaum JL (1991) Proteolipid DM-20 predominates over PLP in peripheral nervous system. Neuroreport 2:89–92PubMedCrossRef Pham-Dinh D, Birling MC, Roussel G, Dautigny A, Nussbaum JL (1991) Proteolipid DM-20 predominates over PLP in peripheral nervous system. Neuroreport 2:89–92PubMedCrossRef
29.
Zurück zum Zitat Pratt VM, Boyadjiev S, Green K, Hodes ME, Dlouhy SR (1995) Pelizaeus–Merzbacher disease caused by a de novo mutation that originated in exon 2 of the maternal great-grandfather of the propositus. Am J Med Genet 58:70–73PubMedCrossRef Pratt VM, Boyadjiev S, Green K, Hodes ME, Dlouhy SR (1995) Pelizaeus–Merzbacher disease caused by a de novo mutation that originated in exon 2 of the maternal great-grandfather of the propositus. Am J Med Genet 58:70–73PubMedCrossRef
30.
Zurück zum Zitat Raskind WH, Williams CA, Hudson LD, Bird TD (1991) Complete deletion of the proteolipid protein gene (PLP) in a family with X-linked Pelizaeus–Merzbacher disease. Am J Hum Genet 49:1355–1360PubMed Raskind WH, Williams CA, Hudson LD, Bird TD (1991) Complete deletion of the proteolipid protein gene (PLP) in a family with X-linked Pelizaeus–Merzbacher disease. Am J Hum Genet 49:1355–1360PubMed
31.
Zurück zum Zitat Readhead C, Schneider A, Griffiths I, Nave KA (1994) Premature arrest of myelin formation in transgenic mice with increased proteolipid protein gene dosage. Neuron 12:583–595PubMedCrossRef Readhead C, Schneider A, Griffiths I, Nave KA (1994) Premature arrest of myelin formation in transgenic mice with increased proteolipid protein gene dosage. Neuron 12:583–595PubMedCrossRef
32.
Zurück zum Zitat Rosenfeld J, Freidrich VL Jr (1983) Axonal swellings in jimpy mice: does lack of myelin cause neuronal abnormalities? Neuroscience 10:959–966PubMedCrossRef Rosenfeld J, Freidrich VL Jr (1983) Axonal swellings in jimpy mice: does lack of myelin cause neuronal abnormalities? Neuroscience 10:959–966PubMedCrossRef
33.
Zurück zum Zitat Saugier-Veber P, Munnich A, Bonneau D et al (1994) X-linked spastic paraplegia and Pelizaeus–Merzbacher disease are allelic disorders at the proteolipid protein locus. Nat Genet 6:257–262PubMedCrossRef Saugier-Veber P, Munnich A, Bonneau D et al (1994) X-linked spastic paraplegia and Pelizaeus–Merzbacher disease are allelic disorders at the proteolipid protein locus. Nat Genet 6:257–262PubMedCrossRef
34.
Zurück zum Zitat Seitelberger F (1995) Neuropathology and genetics of Pelizaeus–Merzbacher disease. Brain Pathol 5:267–273PubMedCrossRef Seitelberger F (1995) Neuropathology and genetics of Pelizaeus–Merzbacher disease. Brain Pathol 5:267–273PubMedCrossRef
35.
Zurück zum Zitat Shy ME, Hobson G, Jain M et al (2003) Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Ann Neurol 53:354–365PubMedCrossRef Shy ME, Hobson G, Jain M et al (2003) Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Ann Neurol 53:354–365PubMedCrossRef
36.
Zurück zum Zitat Simons M, Kramer EM, Macchi P et al (2002) Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus–Merzbacher disease. J Cell Biol 157:327–336PubMedCrossRef Simons M, Kramer EM, Macchi P et al (2002) Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus–Merzbacher disease. J Cell Biol 157:327–336PubMedCrossRef
37.
Zurück zum Zitat Sistermans EA, de Coo RF, de Wijs IJ, van Oost BA (1998) Duplication of the proteolipid protein gene is the major cause of Pelizaeus–Merzbacher disease. Neurology 50:1749–1754PubMed Sistermans EA, de Coo RF, de Wijs IJ, van Oost BA (1998) Duplication of the proteolipid protein gene is the major cause of Pelizaeus–Merzbacher disease. Neurology 50:1749–1754PubMed
38.
Zurück zum Zitat Skoff RP, Bessert DA, Cerghet M et al (2004) The myelin proteolipid protein gene modulates apoptosis in neural and non-neural tissues. Cell Death Differ 11:1247–1257PubMedCrossRef Skoff RP, Bessert DA, Cerghet M et al (2004) The myelin proteolipid protein gene modulates apoptosis in neural and non-neural tissues. Cell Death Differ 11:1247–1257PubMedCrossRef
39.
Zurück zum Zitat Southwood CM, Garbern J, Jiang W, Gow A (2002) The unfolded protein response modulates disease severity in Pelizaeus–Merzbacher disease. Neuron 36:585–596PubMedCrossRef Southwood CM, Garbern J, Jiang W, Gow A (2002) The unfolded protein response modulates disease severity in Pelizaeus–Merzbacher disease. Neuron 36:585–596PubMedCrossRef
40.
Zurück zum Zitat Trapp BD, Peterson J, Ransohoff RM et al (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285PubMedCrossRef Trapp BD, Peterson J, Ransohoff RM et al (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285PubMedCrossRef
41.
Zurück zum Zitat van der Knaap MS, Valk J. (2005) Magnetic resonance of myelin, myelination, and myelin disorders. Springer, New York, p 1084 van der Knaap MS, Valk J. (2005) Magnetic resonance of myelin, myelination, and myelin disorders. Springer, New York, p 1084
42.
Zurück zum Zitat Watanabe I, Patel V, Goebel HH et al (1973) Early lesion of Pelizaeus–Merzbacher disease: electron microscopic and biochemical study. J Neuropathol Exp Neurol 32:313–333PubMedCrossRef Watanabe I, Patel V, Goebel HH et al (1973) Early lesion of Pelizaeus–Merzbacher disease: electron microscopic and biochemical study. J Neuropathol Exp Neurol 32:313–333PubMedCrossRef
43.
Zurück zum Zitat Wilkus RJ, Farrell DF (1976) Electrophysiologic observations in the classical form of Pelizaeus–Merzbacher disease. Neurology 26:1042–1045PubMed Wilkus RJ, Farrell DF (1976) Electrophysiologic observations in the classical form of Pelizaeus–Merzbacher disease. Neurology 26:1042–1045PubMed
44.
Zurück zum Zitat Yamamoto T, Nanba E, Zhang H et al (1998) Jimpymsd mouse mutation and connatal Pelizaeus–Merzbacher disease. Am J Med Genet 75:439–440PubMedCrossRef Yamamoto T, Nanba E, Zhang H et al (1998) Jimpymsd mouse mutation and connatal Pelizaeus–Merzbacher disease. Am J Med Genet 75:439–440PubMedCrossRef
45.
Zurück zum Zitat Yin X, Baek RC, Kirschner DA et al (2006) Evolution of a neuroprotective function of central nervous system myelin. J Cell Biol 172:469–478PubMedCrossRef Yin X, Baek RC, Kirschner DA et al (2006) Evolution of a neuroprotective function of central nervous system myelin. J Cell Biol 172:469–478PubMedCrossRef
Metadaten
Titel
Neuronal loss in Pelizaeus–Merzbacher disease differs in various mutations of the proteolipid protein 1
verfasst von
Anders A. F. Sima
Christopher R. Pierson
Randall L. Woltjer
Grace M. Hobson
Jeffrey A. Golden
William J. Kupsky
Galen M. Schauer
Thomas D. Bird
Robert P. Skoff
James Y. Garbern
Publikationsdatum
01.10.2009
Verlag
Springer-Verlag
Erschienen in
Acta Neuropathologica / Ausgabe 4/2009
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-009-0562-8

Weitere Artikel der Ausgabe 4/2009

Acta Neuropathologica 4/2009 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.